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Nerves made to order
 
y tugging on 
neurons, 
Joseph Fass, 
David Odde, 
and colleagues 
(University of 
Minnesota, 
Minneapolis, MN) 
B
Pulling neurites 
with needles was 
the old, inefficient 
way.
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have taken the first step in their bio-
engineering quest. The eventual goal, 
said Odde, is “to create engineered 
neural networks with defined 
connections.”
Neuron tugging is not a new sport, 
but the old experiments were done with 
glass needles that resulted in inconsistent 
forces and variable results. Fass 
switched to using an electromagnet that 
tugged on magnetic beads coated with 
integrin antibodies. This resulted in 
much more stable force production, 
allowing Fass and Odde to discover two 
novel features of induced neurite 
growth: a sharp transition between no 
outgrowth and relatively speedy outgrowth 
based on small increases in force, and 
transitions between neurite elongation and 
contraction at a fixed level of force.
Force-induced axon elongation occurs 
in vivo during growth of animals, but 
it can also be used to make in vitro 
networks. In a first step in this direction, 
the researchers dropped another nerve 
cell on top of an induced neurite, and 
saw long-lasting adhesions form 
between the cells. They have yet to show 
that this represents a functional synapse.
If synapse formation is succesful, 
Odde plans to use the system to test 
models of neural processing and the 
effects of disease symptoms on this 
processing. For now, he said, he will 
be content if he can “connect cell A to 
cell B.” Eventually he hopes to start 
using a microfabricated version of his 
manipulator, which should allow him 
to manipulate thousands of neurons 
at once.
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Reference:
 
Odde, D.J., and M.J. Renn.
2000. 
 
Biotechnol. Bioeng.
 
 67:312–318.
 
Tearing it up 
 
he initiation of mitosis is a violent event. 
Joël Beaudouin, Jan Ellenberg (EMBL, 
Heidelberg, Germany), and colleagues have 
found that microtubules tug on the nuclear en-
velope, creating folds and invaginations on the 
side nearest them, and rips on the far side. The 
result is a catastrophic beginning to nuclear 
envelope breakdown (NEBD) that allows rapid 
clearing of the nuclear lamina away from chro-
mosomes and the forming spindle.
T
 
Beaudouin’s new model, as he presented it at the meeting, is a departure from 
the two models previously put forward to explain NEBD. The mechanism 
underlying one of those models—phosphorylation-dependent depolymerization 
of nuclear lamins—may take over once the nucleus is breached, but Beaudouin 
did not see significant release of lamins before the large hole opened up. Others 
have proposed that microtubules poke holes in the nuclear envelope, but the 
newly observed holes appear opposite the site where microtubules interact 
with the nuclear envelope.
The nature of the microtubule–nuclear-envelope interaction remains a 
mystery. Beaudoin suggests that a motor, perhaps dynein, might interact with 
nuclear pore complexes. The complexes could then provide a link to the more 
rigid nuclear lamina. Pulling on the pores would produce the 10-
 
 
 
m invaginations 
seen in the nearby sections of the envelope, and the stretching observed on the 
opposite side. The same motors could then power the movement of envelope 
fragments toward the centrosomes, which the researchers saw after the opening 
of the hole. These movements clear the nuclear region to allow the formation of 
a spindle. 
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Reference: Beaudoin, J., et al. 2002. 
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Flu’s hidden virulence factor
 
he influenza genome 
was first characterized 
20 years ago. Now a 
previously undetected 87 
amino acid ORF, PB1-F2, 
has been discovered in 
frame 2 of the PB1 gene 
by Jonathan Yewdell and 
colleagues (National 
T
A flu protein localizes to 
mitochondria.
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Institute of Allergy and Infectious Disease, 
Bethesda, MD). “We believe this is a 
groundbreaking finding,” said Yewdell, 
“although we’re not yet sure how deep 
the ground is.”
Although the PB1-F2 peptide lacks any 
recognizable mitochondrial localization 
signals, it rapidly associates with both the 
inner and outer mitochondrial membranes. 
Minutes after the peptide has been added 
to cells—either by microinjection or direct 
addition to the culture medium—the 
cells show dramatic 
morphological changes. 
Mitochondria vesiculate, 
nuclei shrink, and cells 
round up.
All these activities have 
consequences: infection 
with wild-type virus 
induces apoptosis in 50% 
more cells than a comparable infection 
with mutant virus lacking PB1-F2. 
Daniela Malide, who presented the 
research, suggested one way in which 
PB1-F2 may have a proapoptotic effect. 
She said that the group has very pre-
liminary data suggesting that PB1-F2 
may induce the release of cytochrome 
 
c
 
, a regulator of apoptotic cell death. 
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Reference:
 
Chen, W., et al. 2001. 
 
Nat. Med.
 
7:1306–1312.
A large hole (left) initiates 
nuclear lamina breakdown.
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ntitoxins may become the newest 
weapon in the arsenal against 
anthrax, reported R. John Collier (Harvard 
Medical School, Boston, MA) during a 
special session on the role of cell biologists 
in the battle against bioterrorism.
 
Bacillus anthracis
 
 uses a three-
component toxin system, wherein the 
protective antigen (PA)—the main 
component in anthrax vaccines—helps 
transport two toxin proteins into the 
host cell: edema factor (EF), a calmodulin-
dependent adenylate cyclase, and 
lethal factor (LF), a metalloprotease 
that can clip MAP-kinase kinase. By 
obstructing this transport mechanism, 
Collier and his colleagues hope to 
prevent anthrax fatalities.
Researchers are currently working on 
A
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Death in the middle
 
new three-dimensional (3-D) cell culture system is providing 
substantial clues about the differences between well-mannered, 
noninvasive breast epithelial cells and their malignant cousins, 
according to presentations from Joan Brugge’s research group at 
A
 
Harvard Medical School in Boston, MA.
Brugge used this culture system to show 
that activation of ErbB2, a member of the 
EGF family of growth factor receptors, 
releases epithelial cells from a growth arrest, 
but activation of a closely related receptor, 
ErbB1, does not. These data were surprising 
because both receptors stimulate proliferation 
in a standard 2-D culture dish.
ErbB2 makes mammary acini (left) go 
haywire (right).
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A significant difference between the two culture systems appears 
to be the formation of proper basement membrane attachments. In 
the 3-D system, MCF10A breast epithelial cells form acinus-like 
structures typical of healthy glandular tissue. The acini have a single-
layered ring of well-ordered epithelial cells surrounding a clear 
lumen. After activation of ErbB1, the basement membrane in this 
structure may provide some protection from abnormal proliferation, 
said Kenna Mills, a graduate student with Brugge.
But proliferation is not the whole story. 
ErbB2-expressing cells fill the lumen, a 
signature of early breast cancers, but cells 
expressing the strong oncogene HPV16 E7 
proliferate but then die once they enter the 
lumen. Only with both E7 and an inhibitor 
of apoptosis does the lumen fill with cells.
Jayanta Debnath, who presented much 
of the work, concluded that “multiple 
processes contribute to the formation of the lumen during the 
development of mammary acini,” and that several of these processes 
must go awry during tumor formation. 
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Reference:
 
Muthuswamy, S.K., et al. 2001. 
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 3:785–792.
 
Closing the door on anthrax
 
three antitoxin strategies, but one is 
significantly ahead of the others. Thus far, 
it seems that introducing a dominant-
negative form of the PA protein completely 
disrupts toxin entry into host cytoplasm.
Under normal circumstances, wild-type 
PA binds to a host receptor protein on the 
cell surface, initiating assembly of seven 
PA molecules into a ring. LF and EF bind 
to this heptamer and the whole complex 
enters the host cell by endocytosis. At this 
point, the previously disorganized loops 
in domain two of each of the PA proteins 
form a pore, allowing EF and LF to enter 
into the cytoplasm, where they begin to 
wreak havoc.
However, when Collier’s group 
changes two amino acid residues on the 
lumenal face of PA’s domain two, the 
final transport step is arrested, 
trapping the toxin proteins in the 
endosome. From there the cell trans-
ports them to a lysosome where they 
are destroyed. The strategy works 
even when the mutant form of the 
protein only accounts for 20% of the 
total amount of PA in the infected 
animal, and Collier found that the 
mutant protein can gain access to 
the surface of infected cells after a 
simple intravenous injection.
“I still find it amazing that changing 
two amino acids completely 
blocks translocation,” said Collier. 
He cautioned, however, that further 
animal studies have to be completed 
before the dominant-negative antitoxin 
can be tested for safety in humans.
Researchers also have proof-of-principle 
evidence that two other strategies can 
work in vitro to block toxin entry. They 
can inhibit PA interaction with the cell 
receptor protein, called anthrax toxin 
receptor (ATR), by adding soluble 
receptor fragments to the system in vitro; 
this blocks assembly of the heptamer 
ring and toxin binding. Collier and 
colleagues also find that if they attach 
peptide mimics of the EF and LF 
recognition sequences to a flexible poly-
acrylamide backbone they can saturate 
PA binding sites and significantly reduce 
toxin entry into the cell.
But Collier is most excited about the 
dominant-negative approach. Admitting 
that it may be “a pie-in-the-sky idea,” he 
pointed out that in the best situation the 
dominant-negative antitoxin could have 
two benefits for people exposed to 
anthrax: if they have systemic disease it 
will help to protect the macrophages—
the cells primarily attacked by the toxins—
and if they are not currently infected it 
could act as an immunizing agent to boost 
immune response in case of subsequent 
exposures. 
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Reference: Sellman, B.R., et al. 2001. 
 
Science.
 
292:695–697.
Anthrax toxins make their own doorway into 
the cell.
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Getting off to a great Arp 
 
ctin filaments start from seeds, and 
those seeds are formed by complexes 
containing the actin-related Arp2/3 
proteins. Rows and rows of Arp2/3-
related posters, and several talks, proved 
that these proteins are still commanding 
plenty of attention. Some of the studies 
suggested how Arp2/3
 
 
 
s actions might be 
initiated and then restricted to the front 
of moving cells.
 
Bringing it all together
 
When it comes to building actin 
filaments, seeding is the hardest part. 
Mark Dayel, working with Dyche Mullins 
at the University of California, San 
Francisco, CA, suggests that seeding is 
accomplished using the energy of ATP 
hydrolysis.
He found that Arp2 and Arp3 bind 
ATP with micromolar affinity, and that 
subsequent hydrolysis of the ATP is 
necessary for nucleation of actin 
filaments. Thus hydrolysis may bring 
the two proteins together so they can 
form a nucleus for polymerization of 
the conventional actin monomer. The 
findings were a surprise, as ATP 
hydrolysis is not thought to be important 
for actin polymerization once the Arp 
nucleus is formed.
After nucleation, the ADP-bound 
Arp2/3 complex has a reduced affinity 
for its activators. This may release the 
complex, allowing the activators to be 
recycled. 
 
Reference: Dayel, M.J., et al. 2001. 
 
Proc.
Natl. Acad. Sci. USA.
 
 98:14871–14876.
 
Side or barb?
 
Moving cells need to direct actin poly-
merization forward. Understanding how 
they do that requires an understanding 
of where and how the Arp2/3 complex 
gets its start. This topic has been a source 
of controversy, with some researchers 
convinced that Arp2/3 binds to the side of 
actin filaments, and others equally sure 
that all the action is at filament ends. 
Two related studies presented at the 
conference may have resolved this 
issue with an answer that lies halfway 
in between.
Tom Pollard (Yale University, New 
Haven, CT) and colleagues reported that 
they can directly visualize Arp2/3-
A
Actin branches prefer new (red) not 
old (green) filaments.
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dependent polymerization from the sides 
of existing actin filaments by using total 
internal reflection fluorescence micros-
copy. Such a mechanism is consistent 
with earlier findings that nucleation is 
not prevented by proteins that cap the 
ends of existing actin filaments.
But other workers, such as Marie-France 
Carlier (Centre National de la Recherche 
Scientifique, Gif-sur Yvette, France), have 
noted that parent and daughter actin fila-
ments are generally of the same length, 
suggesting that new filaments branch 
from the ends of old filaments, followed 
by equal growth of new and old filaments. 
A reconciliation of the two points of view 
may have arrived with the findings of John 
Condeelis (Albert Einstein College of 
Medicine, Bronx, NY) and colleagues, 
who suggest that nucleation is dependent 
on an ATP cap that extends a limited 
distance from the end of actin filaments.
Actin binds to filaments in an ATP-
bound form, but this ATP is soon 
hydrolyzed, leaving ADP-bound actin 
in the main body of the filament. 
Condeelis found that branching occurred 
preferentially from newly polymerized 
actin that should be rich in ATP. Studies 
with filaments uniformly loaded with 
particular nucleotides confirmed that 
ATP-bound subunits were needed for 
further branching nucleation.
“It’s great,” said Pollard. “[Condeelis] 
did a different experiment but ended up 
with the same result.” Pollard noted only 
a slight bias of nucleation toward filament 
ends in his assays, but Condeelis believes 
that the bias would be stronger if Pollard 
used lower actin concentrations that 
would favor slower polymerization and 
thus a shorter ATP-bound cap.
The size of that cap is still a matter of 
some disagreement, however. Pollard’s 
new results include a much faster half-
time for actin-dependent ATP hydrolysis, 
measured using new, more accurate 
methods. This would result in a 
vanishingly small ATP cap that in the light 
microscope would be indistinguishable 
from the polymer’s end. Condeelis 
notes, however, that ATP hydrolysis is 
stochastic, and so a mixture of ATP- and 
ADP-bound actin monomers may extend 
for some distance downstream of the 
filament’s end.
For Condeelis, the biochemistry reflects 
back on the biology, and the emphasis on 
ends makes perfect sense. “If you have a 
bias of the branching to the barbed ends,” 
he says, “it would be a perfect way to 
create a structure that would push.” 
 
References: Amman, K.J., and T.D. Pollard.
2001. 
 
Proc. Natl. Acad. Sci. USA.
 
 98:15009–
15013.
Ichetovkin, I., et al. 2002. 
 
Curr. Biol.
 
 12:79–84.
 
Anchoring Arp
 
Even if Arp2/3 activity biases actin poly-
merization forward, the cell may need a 
way to link the resultant protrusion to cell 
adhesion. Kris deMali and Keith Burridge 
(University of North Carolina, Chapel 
Hill, NC) are suggesting that vinculin may 
supply that link. Vinculin is better known 
as a component of focal adhesions, but 
deMali and Burridge detected a direct, 
transient binding of vinculin to the Arp2/3 
complex at the beginning of membrane 
protrusion. The link could give the Arp2/3 
complex a site from which it can push off, 
thus rendering actin polymerization more 
effective. 
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Vinculin (red) may help anchor Arp2/3.
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Stop your blebbing
 
mall molecule inhibitors are beginning 
to reveal the secrets of myosin action. 
In a recent publication and at the meeting, 
Aaron Straight (Harvard Medical School, 
Boston, MA) and colleagues announced 
the discovery of two different myosin 
inhibitors with high specificity.
The first inhibitor, 
 
N
 
-benzyl-
 
p
 
-toluene 
sulphonamide (BTS), hits fast muscle 
myosin II in preference to myosin found in 
Blebbing in cells 
without filamin 
(above) can be 
stopped with 
blebbistatin.
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slow or cardiac muscle or platelets. BTS or its relatives may find 
applications as a muscle relaxant. The second inhibitor, called 
blebbistatin, is specific for nonmuscle myosin II.
The two inhibitors were detected using similar screens. An 
activated form of the target myosin was incubated with ATP and 
one of 16,000 test chemicals. Most chemicals were inactive, 
allowing myosin to chew through the ATP. But a few chemicals 
inhibited ATP hydrolysis. The left-over ATP provided energy for 
luciferase, whose fluorescence identified the positive wells.
The screen yielding BTS went off without a hitch, but the 
pathway to blebbisatin was a little rockier. Resynthesis of what 
Straight thought was the active compound yielded an inactive 
chemical. But when the chemical was left in solvent for a day 
or two, an active breakdown product began to appear. That 
breakdown product was blebbistatin.
Straight has used blebbistatin not only to inhibit the blebbing 
of cells lacking filamin A, but also to inhibit cell motility and 
cytokinesis. Both studies have yielded new insights. When added 
to moving cells, blebbistatin interferes with the cell’s polarity but 
not with protrusion: the confused cell now sends out membrane 
at both its front and back. In dividing cells, blebbistatin prevents 
contraction of the contractile ring, suggesting that a myosin-
independent back-up pathway for cytokinesis seen in 
 
Dictyostelium
 
 
does not exist in vertebrate cells. 
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Reference:
 
Cheung, A., et al. 2002. 
 
Nat. Cell Biol.
 
 4:83–88.
 
Chewing themselves to death
 
ichael Glickman (Technion-Israel Institute of Technology, 
Haifa, Israel) has found a yeast proteasome mutant that 
chews up proteins more rapidly than normal. The phenotype of 
the mutant suggests that yeast stationary phase represents a true 
quiescence.
Glickman has been studying the regulation of proteasomes by 
lopping off the NH
 
2
 
-terminal domains of the 
 
 
 
 subunit proteins, 
thereby creating an open-gate proteasome. These mutant 
proteasomes degrade proteins 
 
 
 
10-fold faster than wild-type 
proteasomes, but the mutant yeast don’t show any growth 
defects—at least not until they are exposed to starvation 
conditions.
If yeast cultures are starved for more than about a week, the 
viability of the proteasome mutants begins to fall off rapidly, 
whereas the wild-type cells are unaffected. Glickman found 
M
 
that wild-type cells react to starvation by shutting down all 
protein degradation, whereas the open-gate mutants continue 
to break down their proteins, a trait that eventually kills them. 
This suggests that stationary phase involves a slowing of all 
metabolism: both the known reduction in synthesis and the 
newly demonstrated reduction in degradation. 
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Reference: Groll, M., et al. 2000. 
 
Nat. Struct. Biol.
 
 7:1062–1067.
The mouth of a mutant proteasome (right) opens too wide.
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Clathrin: from basket weaving to 
muscle contraction
 
ith a new clathrin gene on the scene, get ready to revise 
those dog-eared notions about clathrin-coated pits and 
endocytosis. The new protein, called CHC22—for clathrin 
heavy chain on chromosome 22—shares 85% amino acid 
identity, but little else, with the more familiar form. “It apparently 
has a completely different function [compared to] what we 
normally think of for clathrin and clathrin-coated pits,” said 
Frances Brodsky (University of California, San Francisco, CA).
The new clathrin is predominantly expressed in muscle 
cells, in a pattern that suggests it could be involved in Z-disk 
formation. These disks separate sarcomeres in the myofibrils 
and serve as attachment sites for the thin actin filaments 
required for muscle contraction.
The structural basis for this muscle function is unclear. 
CHC22 forms timeric structures that superficially resemble 
those formed by the previously known clathrin, but these 
structures don’t appear to include clathrin light chains. In fact, 
CHC22 has only weak affinity for the clathrin light chain in 
two-hybrid assays, and Brodsky’s group has yet to find the 
two proteins associated in vivo.
But in a subset of muscular dystrophy patients, the presence of 
the light chain may be critical. Brodsky has hypothesized that in 
these cases the clathrin light chain may be overexpressed, 
enough so that CHC22 may overcome its weak affinity for the 
W
 
light chain and inappropriately 
bind to it. Her group is still 
working on the theory, but for 
now she says “I’m quite excited 
about having studied the bio-
chemistry of clathrin all these 
years and now being able to 
use the information in the study 
of human disease.” 
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Reference: Liu, S.-H., et al. 2001.
 
EMBO J.
 
 20:272–284.
CHC22 (red) and clathrin 
light chain (green) do not 
colocalize (arrows).
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Magical shrinking rafts
 
iochemistry begat rafts, but imaging 
is belittling them. New work 
presented by Anne Kenworthy (Vanderbilt 
University, Nashville, TN) and colleagues, 
and Akihiro Kusumi (Nagoya University, 
Nagoya, Japan) and colleagues suggests 
that rafts are far smaller and more short-
lived than was originally thought.
Rafts are collections of cholesterol, 
sphingolipids, and signaling proteins 
that were initially isolated based on 
their insolubility in certain detergents. 
Deborah Brown (State University of 
New York, Stonybrook, NY) and others 
used that detergent insolubility to determine 
which types of proteins partition into rafts. 
But, says Brown, the biochemistry “doesn’t 
give you any real idea of what the rafts 
look like. In vitro people saw 1-
 
 
 
m sheets, 
and jumped to the conclusion that this is 
what rafts look like. It’s completely clear 
now that that is not true.”
Rafts began to shrink with the work 
of Rajat Varma and Satyajit Mayor 
(National Centre for Biological Sciences, 
Bangalore, India). They used fluorescence 
properties to demonstrate that diluted 
raft proteins remained close together, 
suggesting clusters. But the clusters appeared 
to be less than 70 nm in diameter.
Kenworthy tackled the problem by 
B
 
photobleaching large sections of the 
cell surface and measuring how rapidly 
different proteins diffused back into the 
bleached area. Diffusion was extremely 
rapid, and different raft proteins 
diffused at different rates. Kenworthy 
concludes that raft proteins must exist 
in a variety of dynamically partitioning, 
rather than stable, structures.
Kusumi is attempting to put more 
exact limits on the size and behavior of 
rafts by tracking beads that are attached 
to individual raft proteins. According to 
his measurements, both raft and nonraft 
proteins are constrained primarily by 
cytoskeleton-based fences. The proteins 
wander around 100-nm–diameter 
compartments for 
 
 
 
25 ms before hopping 
to an adjacent compartment, and this 
rate of hopping is slowed only if raft 
proteins are linked together by using 
a bivalent antibody. This suggests that 
rafts must be very small—containing 
perhaps only a few lipid molecules—or 
have half-lives of much less than 25 ms. 
Kusumi notes, however, that these 
properties may change in stimulated 
cells when signaling complexes are 
more active. 
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 1:31–39.
Raft proteins stay uniformly close 
(top) despite overall changes in 
concentration (bottom).
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Make love, not war
 
ice lacking a particular ion channel 
involved in pheromone sensing retain 
a mating response but not an aggression 
response, according to Catherine Dulac 
(Harvard University, Cambridge, MA).
Dulac began by identifying an ion channel, 
TRP2, that is expressed in the lumen of the 
vomeronasal organ (VNO)—the organ 
responsible for pheromone detection in 
rodents. They realized that the location of 
the channel, right at the tip of the microvilli, 
made it a prime candidate for processing the 
pheromone response.
M
TRP2 (red) in the VNO sniffs 
out pheromones.
D
u
l
a
c
/
N
A
S
 
The nature of that response is simple enough. “There may be 
as many as 400 pheromone receptor genes, but only two main 
responses: mating and aggression,” said Dulac. When a 
female mouse is put into a cage that already contains a male 
mouse, the male immediately initiates mating 
behavior. But if the introduced mouse is also 
male, the resident male attacks, as it has 
already come to recognize the space as its 
personal territory.
If the resident male mouse lacks TRP2, 
however, the mutant male tries to mate with 
an introduced mouse regardless of whether it 
is a male or a female.
Based on these data, Dulac concluded 
in her talk that “mating behavior is elicited 
by multiple systems—the VNO and other 
systems—and seems to be the default 
pathway. But aggression behavior relies on the VNO.” 
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Reference: Liman, E.R., et al. 1999. 
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Cellular starvation
 
hile most of us are obsessed with 
apoptotic master regulators, 
pan-tumor suppressors, and cell cycle 
kinases, Craig Thompson (University of 
Pennsylvania, Philadelphia, PA) wishes 
we would remember something a little more 
basic: the intermediary metabolism that we 
left safely back in Biochemistry 101. When 
it comes to controlling whether cells live or 
die, the Glut1 transporter, hexokinase 2, 
and phosphofructokinase 1 are where it’s 
all at, said Thompson. And how did he get 
involved in this glycolytic nightmare? “Not 
by any choice, trust me,” he said.
Thompson is addressing why mammalian 
cells die when a growth factor such as 
interleukin-3 (IL-3) is taken away. He 
believes that the growth factors are 
controlling access to nutrients. In the 
absence of the factors, cells may be starving 
themselves to death even in the midst of 
extracellular plenty.
Initially, Thompson studied how the 
antiapoptotic Bcl-x
 
L
 
 could rescue cells 
denied IL-3. To his surprise, he found 
that Bcl-x
 
L
 
 was restoring exchange of 
ADP into the mitochondria, thus providing 
the mitochondria with a substrate for 
W
Glucose transport helps cells survive 
without growth factors.
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continued ATP production. Thus Bcl-x
 
L
 
 
must be correcting the situation in 
cells lacking IL-3, in which cells were 
deliberately sabotaging the bioenergetics 
of their own mitochondrion. “Why is the 
mitochondria the site of all these forms 
of apoptosis?,” he asked. “It’s because 
cells are reacting to starving to death.”
Further evidence of deliberate starvation 
came when Thompson found that both 
IL-3 and glucose withdrawal induced 
similar drops in glycolytic rate, and 
similar movements of apoptotic regulators. 
IL-3 withdrawal leads to a rapid decline 
in the expression of three major glyco-
lytic regulators, and restoring expression 
of one of these (the Glut1 transporter) 
increases survival from 10 to 30%. 
Thompson said that adding more 
glycolytic proteins back into the cell 
improves the situation even further.
The focus on metabolic control has 
raised doubts in some. Those who study 
growth control, for example, have their 
sights set on regulation of translation, 
not metabolism. But in Thompson’s 
group, he said, “we are arguing that 
protein synthesis is a slave, secondary 
to energy uptake.” Thompson will need 
more data to prove that, but for now 
he believes his model is useful. “At some 
level we realize this will be an over-
simplification,” he said. “But this does 
seem to inform an awful lot of biological 
phenomena.” 
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Mol. Cell. Biol.
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Kinetochore construction
 
ly and human kinetochores appear to be constructed in a 
modular, repeating fashion, according to Mike Blower and 
Gary Karpen (The Salk Institute, La Jolla, CA). They propose that 
the repeats either loop or spiral to form the mitotic kinetochore.
Hints of a repeating structure emerged from earlier studies 
using stretched metaphase chromosomes, but these studies 
relied on the use of autoimmune sera whose protein targets 
were unknown. Blower and Karpen undertook similar studies 
with antibodies to both histone H3 and the H3-like, centromere 
specific protein CENP-A (called CID in flies). In earlier work 
they found that CID localized at fly kinetochores and was 
required for their function.
Looking more closely,
 
 
 
they now find that large domains of 
H3 and CENP-A/CID alternate along interphase chromatin 
when it is isolated using harsh conditions. But gently isolated 
mitotic kinetochores have a single, elliptical ball of CENP-A/CID 
that excludes H3. These two results can be reconciled by a 
model in which one half of each loop or spiral of centromere 
DNA is covered with CID. This organization may present the 
centromere DNA so that it is more accessible to kinetochore 
proteins and microtubules. 
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CID (red) helps organize kinetochores.
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Reference: Blower, M.D., and G.H. Karpen. 2001. 
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A double-agent in DNA repair
 
anconi anemia (FA) 
and Ataxia Telangi-
ectasia (AT) are two 
cancer-susceptibility 
disorders caused by a 
breakdown of DNA 
repair systems. Until 
now the two syndromes 
shared some basic 
similarities but no 
components. Now, 
however, Alan D’Andrea 
and colleagues at the 
Dana-Farber Cancer 
Center in Boston, MA, 
find that one protein is 
F
 
directly involved in both diseases.
When wild-type cells are exposed to DNA cross-linking 
agents, a DNA repair pathway is initiated. The FA complex, 
 
Neutrophils on the move
 
n the 1950’s, David Rogers at Vanderbilt 
University (Nashville, TN) filmed a 
neutrophil in hot pursuit of a 
 
Staphylococcus
 
 
bacterium (see http://zk.bwh.harvard.edu/
projects/motility/neutrophil.html). With 
each twist and turn, the cell reshaped its 
leading edge and detached its rear. Now, 
forty years later, Henry Bourne (University 
of California, San Francisco, CA) is 
mapping out the signaling pathways that 
control such movement in neutrophils. 
His results closely parallel those of Peter 
Devreotes (National Cancer Institute, 
Bethesda, MD) and Rick Firtel (University 
of California, San Diego, CA) in their 
motility studies of the soil amoeba 
 
Dictyostelium discoideum
 
.
In both systems, the chemoattractant 
receptors are uniformly distributed on 
the cell surface but generate an asymmetric 
response that enables the cell to move in 
an organized manner. The first molecule 
in the response pathway to reflect this 
I
 
asymmetry is a membrane lipid, 
phosphatidylinositol-3,4,5-trisphosphate 
(PIP3), which can be detected with a 
protein probe. In the absence of a 
chemoattractant, the probe is uniformly 
distributed in the cytoplasm, but, seconds 
after addition of a chemoattractant, the 
probe concentrates at the leading edge of 
the cell and actin assembly begins in the 
same region.
In neutrophils, this leading edge appears 
to be stabilized and reinforced by feedback 
mechanisms downstream of PIP3. Two of 
the three Rho-GTPase family members—
Rac and Cdc42, but not Rho—are involved. 
Rac and Cdc42 stimulate actin 
polymerization, and inhibition of their 
activity causes the cells to round up, 
losing their leading edges and polarized 
actin assembly, and flattening their PIP3 
gradients. Thus, these GTPases not only 
respond to PIP3, but also mediate a positive 
feedback loop that allows PIP3 to stimulate 
its own accumulation, suggested Bourne. 
And, he pointed out, when Rho is 
inhibited, the back end of the cell is 
slow to detach and move forward. Thus, 
the GTPases work together to convert a 
single external signal into an elaborate 
cascade of activity—and eventually cell 
movement. 
 
RT
 
Reference:
 
Servant, G., et al. 2000. 
 
Science.
 
287:1037–1040.
PIP3 is formed at the leading edge of 
neutrophils.
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consisting of protein subunits encoded by five FA-linked 
genes, becomes active and monoubiquitinates the FANCD2 
protein. Once monoubiquitinated, FANCD2 is recruited to 
a BRCA1 complex and DNA repair begins.
Mutations in any one of eight FA-linked genes can block 
this process, leading to an increased sensitivity to DNA 
cross-linking and an overall increased rate of chromosome 
breakage. In earlier work, D’Andrea’s team found that if 
monoubiquitination of FANCD2 is prevented, then the 
protein doesn’t aggregate with BRCA1 and DNA repair is 
stymied, thus producing FA symptoms.
D’Andrea has now found that mutation of FANCD2 
phosphorylation sites has a very different effect. Lack of 
phosphorylation does not cause FA symptoms or increase 
sensitivity to cross-linking agents, but does block repair by 
AT-related proteins and increase sensitivity to ionizing 
radiation. Thus the FANCD2 protein may integrate inputs 
from the two DNA repair pathways. 
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Reference: Garcia-Higuera, I., et al. 2001. 
 
Mol. Cell.
 
 7:249–262.
FANCD2 is recruited to DNA 
repair sites.
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